Showing results (51-60 of 240) with videos related to

Sort By:
Pageof 24
RMD Open|June 28, 2019
Development of one general and six country-specific algorithms to assess societal health utilities based on ASAS HIIvette Essers, Mickael Hiligsmann, Uta Kiltz, et al.
Pharmacoeconomics|April 13, 2002
A Monte Carlo simulation for modelling outcomes of AIDS treatment regimensAnke Richter, Brett Hauber, Kit Simpson, et al.
The Annals of Pharmacotherapy|February 4, 2010
Patients' benefit-risk preferences for chronic idiopathic thrombocytopenic purpura therapiesA Brett Hauber, F Reed Johnson, Kelly M Grotzinger, et al.
European Journal of Epidemiology|September 4, 2009
Loss of hip bone mineral density over time is associated with spine and hip fracture incidence in osteoporotic postmenopausal womenOlivier Bruyere, Alfredo Roces Varela, Silvio Adami, et al.
Seminars in Arthritis and Rheumatism|February 10, 2019
Cost-effectiveness of sequential treatment with abaloparatide vs. teriparatide for United States women at increased risk of fractureMickael Hiligsmann, Setareh A Williams, Lorraine A Fitzpatrick, et al.
MDM Policy & Practice|November 19, 2021
Exploring Decisional Conflict With Measures of Numeracy and Optimism in a Stated Preference SurveyJessie Sutphin, Rachael L DiSantostefano, Colton Leach, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|February 12, 2011
Eliciting benefit-risk preferences and probability-weighted utility using choice-format conjoint analysisGeorge Van Houtven, F Reed Johnson, Vikram Kilambi, et al.
Current Medical Research and Opinion|November 10, 2015
A discrete-choice experiment to quantify patient preferences for frequency of glucagon-like peptide-1 receptor agonist injections in the treatment of type 2 diabetesA Brett Hauber, Hiep Nguyen, Joshua Posner, et al.
Health Economics|March 10, 2009
Who pays attention in stated-choice surveys?Semra Ozdemir, Ateesha F Mohamed, F Reed Johnson, et al.
Seminars in Arthritis and Rheumatism|March 13, 2020
Cost-effectiveness of sequential treatment with abaloparatide followed by alendronate vs. alendronate monotherapy in women at increased risk of fracture: A US payer perspectiveMickael Hiligsmann, Setareh A Williams, Lorraine A Fitzpatrick, et al.
Pageof 24